Bioconjugation CMC: Successfully Executing a Complex Process

At the CPhI Theater on Tuesday, 30 April 2019, Scott Miller, Senior Scientific Advisor at Carbogen Amcis AG, explored how sponsors should choose a contract manufacturing organization (CMO) when producing antibody drug conjugates (ADCs). Developing ADCs raises several challenges, from its toxic payload, to its several tedious purification steps, to its exacting analytical requirements. Sharing his experiences as both a process sponsor and a CMO representative, Miller offers a comprehensive sense of the selection process that determines the bioprocess.

Fill out the form below to watch his talk now.

Leave a Reply